Nurix Therapeutics Inc
Ownership
Ownership Structure
Who owns Nurix Therapeutics Inc (NRIX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 76.7% of the shares are freely tradable; institutional investors hold 115.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.60 | 8,925,642 | +0.6 | 03/31/2026 |
| Deep Track Capital, LP | 7.45 | 7,736,455 | +21.9 | 06/30/2026 |
| Vestal Point Capital LP | 6.26 | 6,500,000 | +38.6 | 03/31/2026 |
| FMR Inc | 5.34 | 5,541,271 | +30.9 | 03/31/2026 |
| State Street Corp | 4.95 | 5,141,195 | +44.4 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 4.75 | 4,931,999 | +1.0 | 03/31/2026 |
| Baker Bros Advisors LP | 4.49 | 4,658,556 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.27 | 4,427,112 | +0.0 | 03/31/2026 |
| Perceptive Advisors LLC | 4.16 | 4,320,422 | +16.4 | 06/30/2026 |
| Redmile Group, LLC | 3.93 | 4,073,787 | -47.3 | 06/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Hansen Gwenn | Chief Scientific Officer | 117,227 | 2,977,566 $ | Sep 1, 2026 | direct |
| van Houte Hans | Chief Financial Officer | 40,166 | 1,020,216 $ | Aug 4, 2026 | direct |
| Ring Christine | Chief Legal Officer | 9,110 | 231,394 $ | Sep 2, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | Sell | 400 | 26.64 | 10,655 |
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | Sell | 5,387 | 25.69 | 138,417 |
| Sep 2, 2026 | Ring Christine | Chief Legal Officer | Other | 5,787 | 8.72 | 50,463 |
| Sep 1, 2026 | Hansen Gwenn | Chief Scientific Officer | Sell | 1,452 | 25.47 | 36,982 |
| Sep 1, 2026 | Hansen Gwenn | Chief Scientific Officer | Other | 1,452 | 1.86 | 2,701 |
| Aug 5, 2026 | Hansen Gwenn | Chief Scientific Officer | Sell | 4,356 | 25.00 | 108,900 |
| Aug 5, 2026 | Hansen Gwenn | Chief Scientific Officer | Other | 4,356 | 1.86 | 8,102 |
| Aug 4, 2026 | Hansen Gwenn | Chief Scientific Officer | Sell | 2,611 | 24.64 | 64,339 |
| Aug 4, 2026 | Hansen Gwenn | Chief Scientific Officer | Sell | 1,500 | 23.87 | 35,803 |
| Aug 4, 2026 | van Houte Hans | Chief Financial Officer | Sell | 2,967 | 24.65 | 73,129 |
| Aug 4, 2026 | van Houte Hans | Chief Financial Officer | Sell | 1,794 | 23.89 | 42,861 |
| Aug 3, 2026 | Ring Christine | Chief Legal Officer | Sell | 16,589 | 23.05 | 382,358 |
| Aug 3, 2026 | Ring Christine | Chief Legal Officer | Other | 5,787 | 8.72 | 50,463 |
| Jul 30, 2026 | van Houte Hans | Chief Financial Officer | Sell | 2,845 | 23.38 | 66,524 |
| Jul 30, 2026 | van Houte Hans | Chief Financial Officer | Other | 3,572 | 0.00 | – |
| Jul 30, 2026 | van Houte Hans | Chief Financial Officer | Other | 2,858 | 0.00 | – |
| Jul 30, 2026 | van Houte Hans | Chief Financial Officer | Other | 3,750 | 0.00 | – |
| Jul 30, 2026 | Ring Christine | Chief Legal Officer | Sell | 3,847 | 23.38 | 89,954 |
| Jul 30, 2026 | Ring Christine | Chief Legal Officer | Other | 3,572 | 0.00 | – |
| Jul 30, 2026 | Ring Christine | Chief Legal Officer | Other | 2,858 | 0.00 | – |
| Jul 30, 2026 | Ring Christine | Chief Legal Officer | Other | 3,750 | 0.00 | – |
| Jul 30, 2026 | Hansen Gwenn | Chief Scientific Officer | Sell | 3,847 | 23.38 | 89,954 |
| Jul 30, 2026 | Hansen Gwenn | Chief Scientific Officer | Other | 3,572 | 0.00 | – |
| Jul 30, 2026 | Hansen Gwenn | Chief Scientific Officer | Other | 2,858 | 0.00 | – |
| Jul 30, 2026 | Hansen Gwenn | Chief Scientific Officer | Other | 3,750 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.